- Home
- BVN vs RYTM Comparison
BVN vs RYTM Comparison
Compare BVN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- RYTM
- Stock Information
- Founded
- BVN 1953
- RYTM 2008
- Country
- BVN Peru
- RYTM United States
- Employees
- BVN N/A
- RYTM N/A
- Industry
- BVN Metal Mining
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BVN Basic Materials
- RYTM Health Care
- Exchange
- BVN Nasdaq
- RYTM Nasdaq
- Market Cap
- BVN 6.2B
- RYTM 6.4B
- IPO Year
- BVN 1996
- RYTM 2017
- Fundamental
- Price
- BVN $24.56
- RYTM $99.50
- Analyst Decision
- BVN Hold
- RYTM Strong Buy
- Analyst Count
- BVN 1
- RYTM 13
- Target Price
- BVN $15.50
- RYTM $109.77
- AVG Volume (30 Days)
- BVN 1.5M
- RYTM 634.5K
- Earning Date
- BVN 10-30-2025
- RYTM 11-04-2025
- Dividend Yield
- BVN 1.19%
- RYTM N/A
- EPS Growth
- BVN 436.33
- RYTM N/A
- EPS
- BVN 1.98
- RYTM N/A
- Revenue
- BVN $1,307,905,000.00
- RYTM $156,287,000.00
- Revenue This Year
- BVN $15.88
- RYTM $46.10
- Revenue Next Year
- BVN $8.52
- RYTM $60.39
- P/E Ratio
- BVN $12.43
- RYTM N/A
- Revenue Growth
- BVN 32.24
- RYTM 53.55
- 52 Week Low
- BVN $11.50
- RYTM $45.91
- 52 Week High
- BVN $25.46
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- BVN 75.32
- RYTM 53.31
- Support Level
- BVN $23.83
- RYTM $95.88
- Resistance Level
- BVN $25.40
- RYTM $102.79
- Average True Range (ATR)
- BVN 0.83
- RYTM 3.28
- MACD
- BVN 0.16
- RYTM -0.18
- Stochastic Oscillator
- BVN 83.60
- RYTM 53.99
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.